Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 1 - 10 of 426

Selected Filters:
28 July 2026

UNAIDS Special Report for the 26th International AIDS Conference

This report from UNAIDS, prepared for the AIDS 2026 conference, shows how HIV funding disruptions severely impacted HIV prevention, testing, and key components of treatment programmes.

Monitoring & Evaluation, Research, Service Delivery

External Link
10 July 2026

Advancing the Inclusion of Pregnant and Lactating Populations in HIV PrEP Research: Ethical, regulatory, and surveillance recommendations from a multisectoral working group

This article, based on insights from a multi-regional and multi-sectoral working group convened by the Forum for Collaborative Research between January 2024 and February 2025, addresses the critical issue of restriction to PrEP amongst pregnant and lactating people.

Research

External Link
10 July 2026

Long-Acting Injectable Cabotegravir Use and Persistence Over Two Years

This article from JAMA Network Open explores levels of cabotegravir for PrEP uptake and persistence in the US since approval by the US Food and Drug Administration in December 2021.

Research, Service Delivery

External Link
30 June 2026

The Future Won’t Build Itself: Sustaining the Movement CASPR Started

Join AVAC and partners for the launch of the CASPR Impact Report, detailing the achievements of the Coalition to Accelerate & Support Prevention Research (CASPR) over the course of 8+ years. The webinar will share these wins, discuss lessons for the field and provide perspectives on the future of HIV prevention advocacy with AVAC’s global…

Community/Advocacy, Research

Event
23 June 2026

From Insight to Innovation: Integrating user preferences into Multipurpose Prevention Technology development

How can women’s preferences help shape the future of multipurpose prevention technologies? Join IMPT to explore emerging research on user experiences with an investigational vaginal film for HIV prevention and contraception and preferences for multipurpose vaginal rings. Together, these studies highlight the critical role of end-user perspectives in guiding MPT innovation. Presentations: End-user research findings…

Research

Event
18 June 2026

Report on Access to PrEP in Europe, 2026

This 2026 report from AIDS Action Europe (AAE) maps PrEP access across the European Union and European Economic Area and recent developments. It draws on information from AAE member organisations, covering the availability, accessibility, affordability and acceptability of PrEP.

Monitoring & Evaluation, Research, Service Delivery

External Link
18 June 2026

UNAIDS Global AIDS Brief: United to End AIDS

This report from UNAIDS outlines how external funding cuts, a strong push back on human rights, and under investment and under prioritization of HIV prevention and community services are threatening to reverse years of gains in the AIDS response.

Monitoring & Evaluation, Research, Service Delivery

External Link
16 June 2026

Advocates’ Primer: Understanding Bioequivalence and Pharmacokinetic Studies in Next-Generation HIV Prevention Products

As more next-generation PrEP options become available, HIV prevention research is shifting away from large, multi-year efficacy trials toward pharmacokinetic (PK) and bioequivalence (BE) studies — which test whether a new formulation behaves in the body like a product already proven to work. This primer explains the shift and what it means for advocates.

Community/Advocacy, Research

External Link
5 June 2026

Long-Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A cost-effectiveness analysis

This article from Journal of the International AIDS Society assesses the potential clinical and economic impact of offering injectable cabotegravir or lenacapavir to gay and bisexual men who have sex with men and transgender women with high vulnerability to HIV acquisition in Brazil and determines the maximum cost at which they would be cost-effective.

Financing & Costing, Research

External Link
8 May 2026

PrEP Drug Interaction Checker

This website, developed and maintained by the University of Liverpool, provides clear, trustworthy, and up-to-date information about how different PrEP options, including oral PrEP, cabotegravir, lenacapavir, and the dapivirine vaginal ring, can interact with other drugs.

Research, Service Delivery

External Link